Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2011 1
2013 1
2016 2
2018 2
2020 3
2021 1
2022 8
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Primary vaccine failure to routine vaccines: Why and what to do?
Wiedermann U, Garner-Spitzer E, Wagner A. Wiedermann U, et al. Among authors: garner spitzer e. Hum Vaccin Immunother. 2016;12(1):239-43. doi: 10.1080/21645515.2015.1093263. Hum Vaccin Immunother. 2016. PMID: 26836329 Free PMC article. Review.
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation.
Garner-Spitzer E, Wagner A, Gudipati V, Schoetta AM, Orola-Taus M, Kundi M, Kunert R, Mayrhofer P, Huppa JB, Stockinger H, Carsetti R, Gattinger P, Valenta R, Kratzer B, Sehgal ANA, Pickl WF, Reinisch W, Novacek G, Wiedermann U. Garner-Spitzer E, et al. EBioMedicine. 2023 Oct;96:104788. doi: 10.1016/j.ebiom.2023.104788. Epub 2023 Sep 4. EBioMedicine. 2023. PMID: 37672867 Free PMC article.
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: garner spitzer e. Nat Commun. 2022 Sep 12;13(1):5362. doi: 10.1038/s41467-022-33036-y. Nat Commun. 2022. PMID: 36097029 Free PMC article. Clinical Trial.
Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers.
Angelika W, Erika GS, Michael K, Hannes S, Ingrid P, Sabine EH, Peter Q, Oswald W, Ursula W, Katharina GP. Angelika W, et al. Among authors: erika gs. Thromb Res. 2022 Oct;218:142-144. doi: 10.1016/j.thromres.2022.08.005. Epub 2022 Aug 11. Thromb Res. 2022. PMID: 36037550 Free PMC article. No abstract available.
Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P, Kratzer B, Tulaeva I, Niespodziana K, Ohradanova-Repic A, Gebetsberger L, Borochova K, Garner-Spitzer E, Trapin D, Hofer G, Keller W, Baumgartner I, Tancevski I, Khaitov M, Karaulov A, Stockinger H, Wiedermann U, Pickl WF, Valenta R. Gattinger P, et al. Among authors: garner spitzer e. Allergy. 2022 Aug;77(8):2431-2445. doi: 10.1111/all.15305. Epub 2022 Apr 15. Allergy. 2022. PMID: 35357709 Free PMC article.
SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year.
Garner-Spitzer E, Wagner A, Kundi M, Stockinger H, Ohradanova-Repic A, Gebetsberger L, Schoetta AM, Gudipati V, Huppa JB, Kunert R, Mayrhofer P, Kreil TR, Farcet MR, Hoeltl E, Wiedermann U. Garner-Spitzer E, et al. Front Med (Lausanne). 2022 Feb 15;9:822316. doi: 10.3389/fmed.2022.822316. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35242786 Free PMC article.
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
Wagner A, Garner-Spitzer E, Schötta AM, Orola M, Wessely A, Zwazl I, Ohradanova-Repic A, Weseslindtner L, Tajti G, Gebetsberger L, Kratzer B, Tomosel E, Kutschera M, Tobudic S, Pickl WF, Kundi M, Stockinger H, Novacek G, Reinisch W, Zielinski C, Wiedermann U. Wagner A, et al. Among authors: garner spitzer e. Front Immunol. 2022 May 12;13:889138. doi: 10.3389/fimmu.2022.889138. eCollection 2022. Front Immunol. 2022. PMID: 35634285 Free PMC article. Clinical Trial.
Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.
Tobias J, Drinić M, Högler S, Ambroz K, Baier K, Kodajova P, Tomasich E, Berghoff AS, Schmid A, Garner-Spitzer E, Kenner L, Kundi M, Zielinski CC, Wiedermann U. Tobias J, et al. Among authors: garner spitzer e. Transl Oncol. 2022 May;19:101378. doi: 10.1016/j.tranon.2022.101378. Epub 2022 Mar 5. Transl Oncol. 2022. PMID: 35259675 Free PMC article.
23 results